The disorder, also known as male hypogonadism, is the inability of the testicles to produce testosterone, sperm or both.
In July 2005, Indevus licensed the exclusive US rights to Nebido from Schering. Nebido, which was approved and launched in Europe last year, is the first injectable product for treating male hypogonadism requiring dosing only once every three months.
“The finalization of the supply agreement is an important step in bringing Nebido to the market in the US,” said Glenn Cooper, CEO and chairman of Indevus. The company is currently conducting a pharmacokinetic study for Nebido and expects the study to be completed in May 2007.
Indevus Pharmaceuticals is a biopharmaceutical company engaged in the acquisition, development and commercialization of products to treat urological, gynecological and men's health conditions.